Interferon-Β sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models

Molecular Therapy

Volumn 20, Issue 8, 2012, Pages 1529-1539

  Ruotsalainen, Janne ^a   Martikainen, Miika ^a   Niittykoski, Minna ^a   Huhtala, Tuulia ^a   Aaltonen, Tytti ^b   Heikkilä, Jari ^b   Bell, John ^c   Vähä Koskela, Markus ^c   Hinkkanen, Ari ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; CYCLOPHOSPHAMIDE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; NEUTRALIZING ANTIBODY; RAPAMYCIN; RECOMBINANT BETA INTERFERON; SEMLIKI FOREST ALPHAVIRUS VECTOR VA7; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ALPHAVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL DENSITY; CELL VIABILITY; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; GLIOMA; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; PROTEIN INDUCTION; SEMLIKI FOREST ALPHAVIRUS; SINGLE DRUG DOSE; TUMOR CELL CULTURE; TUMOR CELL DESTRUCTION; TUMOR CELL LINE; TUMOR XENOGRAFT; VIRUS REPLICATION;

MUS;

EID: 84864529923     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.53     Document Type: Article

References (50)

1. Määttä, AM, Samaranayake, H, Pikkarainen, J, Wirth, T and Ylä-Herttuala, S (2009). Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther 9: 356-367.
2. Zemp, FJ, Corredor, JC, Lun, X, Muruve, DA and Forsyth, PA (2010). Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev 21: 103-117.
3. Parker, JN, Bauer, DF, Cody, JJ and Markert, JM (2009). Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6: 558-569.
4. Heikkilä, JE, Vähä-Koskela, MJ, Ruotsalainen, JJ, Martikainen, MW, Stanford, MM, McCart, JA et al. (2010). Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS ONE 5: e8603.
5. Ketola, A, Hinkkanen, A, Yongabi, F, Furu, P, Määttä, AM, Liimatainen, T et al. (2008). Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res 68: 8342-8350.
6. Määttä, AM, Liimatainen, T, Wahlfors, T, Wirth, T, Vähä-Koskela, M, Jansson, L et al. (2007). Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer 121: 863-870.
7. Määttä, AM, Mäkinen, K, Ketola, A, Liimatainen, T, Yongabi, FN, Vähä-Koskela, M et al. (2008). Replication competent Semliki Forest virus prolongs survival in experimental lung cancer. Int J Cancer 123: 1704-1711.
8. Vähä-Koskela, MJ, Heikkilä, JE and Hinkkanen, AE (2007). Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216.
9. Vähä-Koskela, MJ, Kallio, JP, Jansson, LC, Heikkilä, JE, Zakhartchenko, VA, Kallajoki, MA et al. (2006). Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res 66: 7185-7194.
10. Vähä-Koskela, MJ, Tuittila, MT, Nygårdas, PT, Nyman, JK, Ehrengruber, MU, Renggli, M et al. (2003). A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. J Neurovirol 9: 1-15.
11. Tuittila, MT, Santagati, MG, Röyttä, M, Määttä, JA and Hinkkanen, AE (2000). Replicase complex genes of Semliki Forest virus confer lethal neurovirulence. J Virol 74: 4579-4589.
12. Kirn, D (2001). Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 1: 525-538.
13. Grieder, FB and Vogel, SN (1999). Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. Virology 257: 106-118.
14. Fragkoudis, R, Breakwell, L, McKimmie, C, Boyd, A, Barry, G, Kohl, A et al. (2007). The type I interferon system protects mice from Semliki Forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons. J Gen Virol 88(Pt 12): 3373-3384.
15. Ryman, KD, Klimstra, WB, Nguyen, KB, Biron, CA and Johnston, RE (2000). Interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J Virol 74: 3366-3378.
16. McFadden, G, Mohamed, MR, Rahman, MM and Bartee, E (2009). Cytokine determinants of viral tropism. Nat Rev Immunol 9: 645-655.
17. Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878.
18. Ikeda, K, Ichikawa, T, Wakimoto, H, Silver, JS, Deisboeck, TS, Finkelstein, D et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5: 881-887.
19. Ikeda, K, Wakimoto, H, Ichikawa, T, Jhung, S, Hochberg, FH, Louis, DN et al. (2000). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 74: 4765-4775.
20. Qiao, J, Wang, H, Kottke, T, White, C, Twigger, K, Diaz, RM et al. (2008). Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 14: 259-269.
21. Lun, XQ, Jang, JH, Tang, N, Deng, H, Head, R, Bell, JC et al. (2009). Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 15: 2777-2788.
22. Lun, X, Chan, J, Zhou, H, Sun, B, Kelly, JJ, Stechishin, OO et al. (2010). Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther 18: 1927-1936.
23. Alain, T, Lun, X, Martineau, Y, Sean, P, Pulendran, B, Petroulakis, E et al. (2010). Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA 107: 1576-1581.
24. Schiavoni, G, Mattei, F, Di Pucchio, T, Santini, SM, Bracci, L, Belardelli, F et al. (2000). Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030.
25. van der Most, RG, Currie, AJ, Cleaver, AL, Salmons, J, Nowak, AK, Mahendran, S et al. (2009). Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS ONE 4: e6982.
26. Willmon, C, Diaz, RM, Wongthida, P, Galivo, F, Kottke, T, Thompson, J et al. (2011). Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther 19: 140-149.
27. Makhani, N, Gorman, MP, Branson, HM, Stazzone, L, Banwell, BL and Chitnis, T (2009). Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 72: 2076-2082.
28. Radis, CD, Kahl, LE, Baker, GL, Wasko, MC, Cash, JM, Gallatin, A et al. (1995). Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 38: 1120-1127.
29. Binder, GK and Griffin, DE (2001). Interferon-gamma-mediated site-specific clearance of alphavirus from CNS neurons. Science 293: 303-306.
30. Scallan, MF and Fazakerley, JK (1999). Aurothiolates enhance the replication of Semliki Forest virus in the CNS and the exocrine pancreas. J Neurovirol 5: 392-400.
31. Erälinna, JP, Röyttä, M, Hukkanen, V, Zinhu, D, Salmi, AA and Salonen, R (1998). Selective downregulation of Th1 response by Linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice. J Neuroimmunol 88: 165-176.
32. Sawicki, DL and Sawicki, SG (1980). Short-lived minus-strand polymerase for Semliki Forest virus. J Virol 34: 108-118.
33. Sawicki, DL, Sawicki, SG, Keränen, S and Kääriäinen, L (1981). Specific Sindbis viruscoded function for minus-strand RNA synthesis. J Virol 39: 348-358.
34. Sawicki, SG, Sawicki, DL, Kääriäinen, L and Keränen, S (1981). A Sindbis virus mutant temperature-sensitive in the regulation of minus-strand RNA synthesis. Virology 115: 161-172.
35. Wollmann, G, Robek, MD and van den Pol, AN (2007). Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol 81: 1479-1491.
36. Mosca, JD and Pitha, PM (1986). Transcriptional and posttranscriptional regulation of exogenous human interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol 6: 2279-2283.
37. Yu, SC, Ping, YF, Yi, L, Zhou, ZH, Chen, JH, Yao, XH et al. (2008). Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 265: 124-134.
38. Patel, SJ, King, KR, Casali, M and Yarmush, ML (2009). DNA-triggered innate immune responses are propagated by gap junction communication. Proc Natl Acad Sci USA 106: 12867-12872.
39. Xie, M, Yi, C, Luo, X, Xu, S, Yu, Z, Tang, Y et al. (2011). Glial gap junctional communication involvement in hippocampal damage after middle cerebral artery occlusion. Ann Neurol 70: 121-132.
40. Bilello, JP, Cable, EE, Myers, RL and Isom, HC (2003). Role of paracellular junction complexes in baculovirus-mediated gene transfer to nondividing rat hepatocytes. Gene Ther 10: 733-749.
41. Wang, G, Zabner, J, Deering, C, Launspach, J, Shao, J, Bodner, M et al. (2000). Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo. Am J Respir Cell Mol Biol 22: 129-138.
42. Esclatine, A, Lemullois, M, Servin, AL, Quero, AM and Geniteau-Legendre, M (2000). Human cytomegalovirus infects Caco-2 intestinal epithelial cells basolaterally regardless of the differentiation state. J Virol 74: 513-517.
43. Wang, G, Davidson, BL, Melchert, P, Slepushkin, VA, van Es, HH, Bodner, M et al. (1998). Influence of cell polarity on retrovirus-mediated gene transfer to differentiated human airway epithelia. J Virol 72: 9818-9826.
44. Cohen, CJ, Shieh, JT, Pickles, RJ, Okegawa, T, Hsieh, JT and Bergelson, JM (2001). The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 98: 15191-15196.
45. Meager, A (2002). Biological assays for interferons. J Immunol Methods 261: 21-36.
46. Huang, PY, Guo, JH and Hwang, LH (2012). Oncolytic sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol Ther 20: 298-305.
47. Streck, CJ, Dickson, PV, Ng, CY, Zhou, J, Hall, MM, Gray, JT et al. (2006). Antitumor efficacy of AAV-mediated systemic delivery of interferon-?. Cancer Gene Ther 13: 99-106.
48. Qin, XQ, Beckham, C, Brown, JL, Lukashev, M and Barsoum, J (2001). Human and mouse IFN-gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol Ther 4: 356-364.
49. Alexenko, AP, Ealy, AD and Roberts, RM (1999). The cross-species antiviral activities of different IFN-tau subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential. J Interferon Cytokine Res 19: 1335-1341.
50. Santagati, MG, Itäranta, PV, Koskimies, PR, Määttä, JA, Salmi, AA and Hinkkanen, AE (1994). Multiple repeating motifs are found in the 3CO-terminal non-translated region of Semliki Forest virus A7 variant genome. J Gen Virol 75 (Pt 6): 1499-1504.